Injectable Drug Delivery Market Size To Reach US$ 1388.13 Bn By 2032

The global injectable drug delivery market size reached US$ 649.8 billion in 2023 and is projected to surpass US$ 1388.13 billion by 2032 with a CAGR of 8.80% from 2023 to 2032.

Key Points:

North America has accounted 46% revenue share in 2022.
By device type, the prefilled syringes segment has held market share of over 58% in 2022 and it is growing at a CAGR of 9.5% over the forecast period.
By therapeutic application, the oncology segment has held highest revenue share 44% in 2022.
By distribution channel, the hospitals and clinics segment has captured market share of around 61% in 2022.

The rising prevalence of cancer is one of the major factors driving the global injectable drugs delivery market. Furthermore, governments all over the world are contributing to the worldwide injectable drug market’s expansion. The government is investing extensively in the development and commercialization of innovative injectable drugs delivery. The fierce battle in the worldwide injectable drugs delivery market is united in form due to the vast product range and impressive distribution network of significant enterprises in both emerging and existing nations. Significant expenditure for the development of novel and cutting-edge technology, as well as the introduction of distinctive goods such as sophisticated wearable devices and gadgets, are some of the principal methods used by big market players.

Get the Sample Pages of Report@ https://www.precedenceresearch.com/sample/1760

Regional Snapshot

North America is the largest segment for injectable drugs delivery market in terms of region. The rising prevalence of various illnesses is being blamed for the expansion of the injectable drugs delivery market in the North American area. Furthermore, the market for injectable drugs delivery in North America is growing due to increased adoption of tactics by industry participants.

Europe region is the fastest growing region in the injectable drugs delivery market. The UK hold the highest market share in the Europe injectable drugs delivery market. Factors like the increase of the biologics market, the rising frequency of chronic illnesses, and the expanding demand for self-injection devices are all contributing to this trend in the European injectable drugs delivery industry. Other reasons driving the expansion of the injectable drugs delivery industry in Europe are rising disposable income, increased partnership numbers, and more awareness of safety and comfort.

Report Highlights

On the basis of type, devices segment holds the largest market share in the global injectable drugs delivery market. As the prevalence of chronic illnesses rises, so does the use of needles in general, particularly disposable syringes. Because population growth is thought to be the most important element in emerging countries, it is likely to have the high effect on the segment.
On the basis of therapeutic application, auto-immune diseases segment holds the largest market share in the global injectable drugs delivery market. In auto-immune illnesses, the immune system targets and kills its own body tissue. Among the most common are lupus and diabetes.
On the basis of distribution channel, hospitals segment holds the largest market share in the global injectable drugs delivery market. The surge in number of persons admitted to healthcare centers such as hospitals with chronic and acute wounds is to blame.

Table of Contents

Infant Injectable Drug Delivery Market Scope

Report Coverage	Details
Market Size by 2032	USD 1388.13 Billion
Growth Rate from 2023 to 2032	CAGR of 8.80%
Largest Market	North America
Fastest Growing Market	Europe
Base Year	2022
Forecast Period	2023 to 2032
Segments Covered	Type, Formulation Packaging, Therapeutic Application, Usage Pattern, Site of Administration, Distribution Channel, Facility of Use, Geography

Infant Injectable Drug Delivery Market Dynamics

Drivers

Surge in demand for contraceptive drugs

In 2012, over 1,697,000 women in the U.S. utilized injectable contraception, as per the Guttmacher Institute. The injectable contraceptives have become increasingly popular throughout the years. The great effectiveness of injectable contraceptives accounts for the rising use of these products. As a result, surge in demand for contraceptive drugs is driving the growth of global injectable drugs delivery market.

Restraints

Growing preference for other mode of delivery

The injectable drugs delivery administration provides a high surface area for absorption, allowing for rapid systemic administration. The injectable drugs delivery, however, cause needlestick infections and injuries, as well as needle fear and pain. To some extent, all of these constraints are restricting the growth of global injectable drugs delivery market.

Opportunities

Rising market for biologics

As per the Economist, over 900 biologics are being developed in the U.S. for the treatment of over 100 disorders. Biologics are the fastest growing section of the pharmaceutical industry, as per the American Journal of Managed Health Care. According to a PHARMAC report, worldwide expenditure on all medications climbed by 24% between 2007 and 2012, but expenditure on biologics rose by 367% within the same time period. Thus, rising market for biologics is supporting the growth of worldwide injectable drugs delivery market.

Challenges

Product recall

When a product is evoked, the procedure of collection and replacement the faultyproducts can result in substantial losses for the firm or supplier. These massive losses will have an influence on the company’s market share and revenue share, which will have an impact on the growth of the global injectable drugs delivery market over the projected period.

Key Developments

BD bought CareFusion Corporation in March 2015 to broaden its capabilities and improve drug management and patient safety. In the same year, BD purchased CRISI Medical Systems, a medical technology business, in order to improve the efficiency of drug delivery via IV injectables. BD has a worldwide presence in 50 nations, allowing it to maintain its position in the global market.
Pfenex Inc. announced in June 2020 that Alvogen, its commercialization partner, had introduced Teriparatide Injection in the U.S. for a variety of indications, including postmenopausal women with osteoporosis who are at high risk of broken bones.
Terumo Corporation teamed up with Ypsomed Group in 2014. The organization combined their prefillable polymer syringe, PLAJEX, with YpsoMate as a result of this agreement. This aided the corporation in strengthening their syringe product offerings.
Sanford-Burnham Medical Research Institute and Eli Lilly and Company formed a partnership in 2015 to explore immunological therapeutics for inflammatory bowel disorder, lupus, and autoimmune diseases. The expertise of both institutions will be pooled to discover novel treatments for these disorders.

Infant Injectable Drug Delivery Market Companies

Becton
Dickinson and Company
Pfizer Inc.
Teva Pharmaceuticals Industries Ltd.
Eli Lilly and Company
Baxter International, Inc.
Sandoz
Terumo
Schott AG
Gerresheimer
Ypsomed
Bespak
B. Braun Melsungen

Segments Covered in the Report

By Type

Devices
- Conventional Injectables
- Pre-Filled Syringes
- Auto-Injectors
- Pen-Injectors
Formulations

By Formulation Packaging

Ampules
Vials
Cartridges
Bottles

By Therapeutic Application

Auto-immune diseases
Hormonal Disorders
Orphan Diseases
Oncology
Others

By Usage Pattern

Curative Care
Immunization
Other

By Site of Administration

Skin
Circulatory/Musculoskeletal
Organs
Central Nervous System

By Distribution Channel

Hospitals & Clinics
Retail Pharmacy Stores
Others

By Facility of Use

Hospitals & Clinics
Home Care Settings
Other

By Geography

North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa